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TO THE EDITOR
Generalized pustular psoriasis (GPP)
often presents in patients with existing
or prior psoriasis vulgaris (PV), although
cases of GPP have been known to arise
without a history of PV. We recently
reported that the majority of the cases of
GPP without a history of PV (‘‘GPP
alone’’) are caused by homozygous
or compound heterozygous mutations
of IL36RN (Sugiura et al., 2013). In
contrast, only a few exceptional cases
of GPP that were preceded or accom-
panied by PV (‘‘GPP with PV’’) were
found to have IL36RN mutations. Thus,
GPP with PV is genetically different
from GPP alone.
CARD14 encodes caspase recruit-
ment domain family member 14
(CARD14), which is an activator of
nuclear factor of k-light-chain-enhancer
of activated B cells within the epi-
dermis. Jordan et al. (2012a, b) identi-
fied rare gain-of-function variants
and mutations in CARD14, including
p.Gly117Ser, in two large multiplex
families affected by Mendelian
forms of psoriasis and psoriatic arthritis
(Figure 1). Autosomal dominant pityria-
sis rubra pilaris, which is phenotypically
related to psoriasis, was also reported
to be caused by mutations in CARD14
(Fuchs-Telem et al., 2012), including
p.Glu138del and p.Leu156Pro. More-
over, CARD14 p.Arg820Trp (rs11652075)
was found to be a PV-susceptible variant
in a large psoriasis cohort (Tsoi et al.,
2012; Jordan et al., 2012a). Therefore,
CARD14 variants and mutations are
closely related to various types of psori-
asis and psoriasis-related diseases.
Jordan et al. (2012b) identified the rare
de novo CARD14 gain-of-function vari-
ant p.Glu138Ala in a child with severe
early-onset GPP. They found three other
rare CARD14 gain-of-function vari-
ants in large PV cohorts including
p.Asp176His. There was no association
of the p.Asp176His variant with PV
because the rare variant was found not
only in the large PV cohorts but also in
the large control cohorts.
The present study aimed to investigate
the presence of CARD14 variants in
GPP with PV. We analyzed the entire
coding regions of CARD14 in 19 cases
of GPP with PV and in 11 cases of
GPP alone. Then, we analyzed exon 4
of CARD14 in the 100 cases of PV and
the 100 healthy controls that we had
previously studied (Sugiura et al., 2013).
All cases and controls were Japanese.
It was previously reported that 9 out of
11 cases of GPP alone had homozygous
or compound heterozygous IL36RN
mutations (Sugiura et al., 2013). The
clinical characteristics of the 30
patients with GPP and the 100 patients
with PV are indicated in Supplementary
Table S1 and S2 online, respectively.
Following approval from the Ethics
Committee of Nagoya University,
written informed consent was obtained
from all participants in compliance
with the Declaration of Helsinki
guidelines.
The sequence primers for analysis of
CARD14 are indicated in Supplemen-
tary Table S3 online. Direct-sequencing
analysis of the entire coding regions of
CARD14 with exon–intron boundaries
revealed 4 of the 19 cases of GPP with
PV to be heterozygous for c.526G4C
(p.Asp176His) (Figure 2). We found no
other mutations or variants. However,
none of the 11 cases of GPP alone
had any variants. Among the cases
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Figure 1. Caspase recruitment domain family, member 14 (CARD14) protein domain structure,
locations of amino acid substitutions and deletions, and related psoriatic diseases. CARD and coiled-coil
domains are essential for nuclear factor of kappa-light-chain-enhancer of activated B cells (NF-kB)
activation. The PDZ, SH3, and GUK domains are proposed as being essential for membrane localization
and lipid raft recruitment of CARD14 protein (Scudiero et al., 2011). Rare and common variants and
mutations found are indicated. p.Asp176His is the generalized pustular psoriasis (GPP) with psoriasis
vulgaris (PV)-susceptible variant shown in the present study. p.Arg820Trp is the PV-susceptible variant
(Tsoi et al., 2012; Jordan et al., 2012a). p.Gly117Ser is a mutation found in the family of Mendelian
autosomal dominant (AD) PV and psoriatic arthritis (PA; Jordan et al., 2012a). p.Glu138Ala was found in
a patient with early-onset GPP. p.Glu138del and p.Leu156Pro indicate that the mutations found
in AD pityriasis rubra pilaris (RPR; Fuchs-Telem et al., 2012). CARD, caspase recruitment domain;
GUK, guanylate kinase; PDZ, a domain from the initial letters of the PSD-95, Dlg, and ZO-1 proteins;
SH3, src homology 3.
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with homozygous or compound hetero-
zygous IL36RN mutations, no cases had
the variant c.526G4C (p.Asp176His).
Direct-sequencing analysis of exon 4,
which encodes p.Asp176, revealed 4
out of the 100 cases of simple PV and
3 out of the 100 healthy controls to have
the heterozygous variant c.526G4C
(p.Asp176His). The carrier rate of the
p.Asp176His variant in GPP with PV (4/
19: 21.1%) was significantly higher
compared with that in the controls (3/
100: 3%; Fisher exact test: Po0.0123;
odds ratio of 8.62; confidence intervals
between 1.75 and 42.4; power calcu-
lation of 0.609). However, there was
no significant difference in the carrier
rate of p.Asp176His between GPP alone
(0/11: 0%) and the healthy controls.
Jordan et al. (2012a) reported that
p.Asp176His was found in 2 out of
1609 controls in European populations.
The carrier rate of p.Asp176His in the
Japanese individuals in the present study
is significantly higher compared with
that in the European cohort (Po0.01;
Jordan et al., 2012a). The Ensembl
genome browser indicates that 3 out
of 178 alleles in the Japanese popu-
lation have c.526G4C. This frequency
is very close to the 3 out of 200 alleles
of the present study. We conclude
that the CARD14 variant p.Asp176His
is an important predisposing factor
for GPP with PV in the Japanese
population.
Because of the low number of
patients, the current study is under-
powered to detect variants at low
frequencies, such as pGlu138Ala, in
this population (Jordan et al., 2012a).
pGlu138Ala was reported in an early-
onset GPP patient, although the
mutant was not found in any of the 30
GPP patients in the present study.
HLA-Cw*602 is the main genetic
predisposing factor for psoriasis. We
analyzed HLA-C in the 30 patients
with GPP and the 100 patients with
PV using Micro SSPTM HLA typing
trays (One Lambda, Canoga Park,
CA; Supplementary Tables S1 and S2
online). No interaction was found bet-
ween the CARD14 variant c.526G4C
and HLA-Cw*602.
The haplotype block structure flank-
ing the CARD14 gene was constructed
using genotype data from the HapMap
database. We analyzed the haplotypes
of 200 alleles of the controls. The
haplotype block was represented by
eight haplotypes (Supplementary Figure
S1 online). In all, 11 individuals carrying
the CARD14 variant c.526G4C
(p.Asp176His), the chromosome con-
taining c.526G4C, had an identical
haplotype, haplotype III (GGACCTC
CA), which is seen in 11.5% of the
Japanese population. Thus, the variant
c.526G4C (p.Asp176His) in the present
Japanese individuals appears to repre-
sent founder effects of the prevalent
variant CARD14 alleles among indivi-
duals in this island nation.
In this study, we found that CARD14
p.Asp176His is a prevalent founder var-
iant in the Japanese population and is a
predisposing factor for GPP with PV. In
contrast, CARD14 p.Asp176His is not
associated with PV in the Japanese
population. These findings suggest that
GPP with PV has a genetic background
different from that of simple PV. In
addition, no patient with GPP alone
has had CARD14 p.Asp176His,
although the majority have had IL36RN
mutations, as previously reported
(Sugiura et al., 2013). In this context,
the present results further support the
idea that GPP with PV is genetically
different from GPP alone.
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Figure 2. Carrier rate and allele frequency of p.Asp176His in generalized pustular psoriasis (GPP)
with psoriasis vulgaris (PV), and in PV. The carrier rate (a) and allele frequency (b) of p.Asp176His in
GPP with PV are significantly higher compared with those in PV and in healthy controls. *Po0.05.
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TO THE EDITOR
Wound healing is a complex process
involving cell–cell and cell–matrix inter-
actions modulated by the surrounding
microenvironment. One of the key
events in this process is re-epithelializa-
tion: the directed migration and prolif-
eration of epithelial cells to resurface the
wound. Numerous studies have docu-
mented that the migration of cells into
the wound site is regulated by autocrine
and paracrine signaling of growth fac-
tors (Gurtner et al., 2008). Epidermal
growth factor (EGF) is an extensively
investigated growth factor, which is
implicated in keratinocyte adhesion
and migration, as well as fibroblast func-
tion, and granulation tissue formation
(Hardwicke et al., 2008). Conflicting
reports exist regarding the ability of
EGF alone to modulate wound healing
(Brown et al., 1989; Cohen et al., 1995).
A systematic review concluded that EGF
is effective as an adjuvant but not as
monotherapy for diabetic foot ulcers
(Buchberger et al., 2011). The reason
for this lack of efficacy of EGF in healing
wounds may be derived from the
mechanism of delivery, in that it needs
to be intimately associated with the
extracellular matrix to limit proteolysis
(Macri and Clark, 2009).
Various approaches for delivering
EGF to the wound have been attempted
with the goal of maximizing therapeutic
effects with minimal dose (to minimize
potential adverse effects). EGF conju-
gated to copolymers composed of
poly(e-caprolactone) (PCL) and poly
(ethyleneglycol) (PEG) improved healing
in diabetic mouse wounds, compared
with treatment with the copolymers
alone or no treatment (Choi et al.,
2008). Recent advances in materials
science have led to the development
of engineered systems such as poly-
meric microparticles for controlled
release of cytoactive factors (CFs; Lee
et al., 2011). Another method that has
received limited attention is the
covalent immobilization of CFs within
polyelectrolyte multilayer (PEM) films.
PEM films, which are formed by the
layer-by-layer deposition of polyelectro-
lytes, provide numerous advantages for
biomedical applications, such as ease of
preparation, biocompatibility, tunable
mechanical properties, spatio-temporal
control over film organization, and most
importantly, the sustained and contro-
lled contact of embedded factors with
tissue (Guthrie et al., 2013). In parti-
cular, we speculate that the nanoscopic
thickness of PEMs enables their intimate
contact with the tissue surface upon
application. When CFs are conjugated
to the PEMs, it also limits, if not
eliminates, the systemic release of
embedded CFs and the associated
potential for systemic toxicity (Agarwal
et al., 2010). Another key advantage
of the PEM films is that they can also
be easily immobilized to complex
geometries such as wound bed (Jain
et al., 2013). However, the efficacy, bio-
availability, and bioactivity of CFs such
as growth factors, when conjugated to
PEMs, have not been reported.
To address the question of the bio-
availability of growth factors within
PEMs, we fabricated PEM films with
EGF that was covalently immobilized
at varying depths within the PEMs.
The accessibility and bioactivity of
EGF immobilized within the PEM films
was determined by measuring the
migratory and proliferative responses ofAccepted article preview online 3 January 2013; published online 23 January 2014
Abbreviations: CF, cytoactive factor; EGF, epidermal growth factor; HKGS, human keratinocyte growth
supplement; NHK, neonatal human keratinocyte; PAA, poly(acrylic acid); PAH, poly(allylamine
hydrochloride); PEM, polyelectrolyte multilayer
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